The stock of Vascular Solutions, Inc. (NASDAQ:VASC) reached all time high today, Nov, 29 and still has $56.98 target or 6.00% above today’s $53.75 share price. This indicates more upside for the $937.22 million company. This technical setup was reported by Barchart.com. If the $56.98 PT is reached, the company will be worth $56.23 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 33,885 shares traded hands. Vascular Solutions, Inc. (NASDAQ:VASC) has risen 46.25% since April 26, 2016 and is uptrending. It has outperformed by 40.99% the S&P500.
Analysts await Vascular Solutions, Inc. (NASDAQ:VASC) to report earnings on January, 19. They expect $0.34 EPS, up 3.03% or $0.01 from last year’s $0.33 per share. VASC’s profit will be $5.93 million for 39.52 P/E if the $0.34 EPS becomes a reality. After $0.31 actual EPS reported by Vascular Solutions, Inc. for the previous quarter, Wall Street now forecasts 9.68% EPS growth.
Vascular Solutions, Inc. (NASDAQ:VASC) Ratings Coverage
Out of 3 analysts covering Vascular Solutions (NASDAQ:VASC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vascular Solutions has been the topic of 3 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Needham initiated Vascular Solutions, Inc. (NASDAQ:VASC) rating on Thursday, October 6. Needham has “Buy” rating and $58 price target. The rating was maintained by Piper Jaffray on Tuesday, August 11 with “Overweight”.
According to Zacks Investment Research, “Vascular Solutions Inc. manufactures, markets and sells the Vascular Solutions Duett sealing device, which enables cardiologists and radiologists to rapidly seal the puncture site following catheterization procedures such as angiography, angioplasty and stenting. Its product combines a simple balloon catheter delivery mechanism with a powerful, proprietary procoagulant. The company believes its product offers advantages over both manual compression and the three other FDA-approved devices used to seal the puncture site following the catheterization.”
Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.01, from 1.19 in 2016Q1. The ratio increased, as 10 funds sold all Vascular Solutions, Inc. shares owned while 44 reduced positions. 15 funds bought stakes while 49 increased positions. They now own 14.00 million shares or 4.98% more from 13.33 million shares in 2016Q1.
Blackrock Inv Ltd Co holds 0% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 74,611 shares. Barclays Public Ltd Company, a United Kingdom-based fund reported 5,117 shares. Mairs & Inc holds 0.04% or 75,653 shares in its portfolio. Cadence Cap Mgmt Lc accumulated 21,385 shares or 0.07% of the stock. Ami Asset Mgmt Corporation last reported 272,515 shares in the company. Pub Sector Pension Investment Board holds 0.01% of its portfolio in Vascular Solutions, Inc. (NASDAQ:VASC) for 11,948 shares. Kalmar Invests Inc De owns 237,685 shares or 0.44% of their US portfolio. California State Teachers Retirement has 0% invested in the company for 35,343 shares. Moreover, Next Century Growth Limited Liability Corporation has 0.1% invested in Vascular Solutions, Inc. (NASDAQ:VASC) for 53,028 shares. Bnp Paribas Arbitrage Sa, a New York-based fund reported 6,772 shares. Driehaus Cap Management Limited Liability Co reported 121,183 shares or 0.18% of all its holdings. Capital Impact Advsr Limited Liability has 0.58% invested in the company for 29,709 shares. Henderson Public Ltd Company owns 58,499 shares or 0.02% of their US portfolio. Bank Of Montreal Can has 0% invested in the company for 4,848 shares. Deutsche Commercial Bank Ag last reported 29,363 shares in the company.
Insider Transactions: Since July 27, 2016, the stock had 0 insider buys, and 2 sales for $2.27 million net activity. 10,011 Vascular Solutions, Inc. (NASDAQ:VASC) shares with value of $463,109 were sold by RUTSTEIN WILLIAM. On Wednesday, July 27 the insider ROOT HOWARD sold $1.80M.
More news for Vascular Solutions, Inc. (NASDAQ:VASC) were recently published by: Globenewswire.com, which released: “Vascular Solutions Receives 510(k) Clearance for Fluentâ„¢ Inflation Device” on October 21, 2016. Globenewswire.com‘s article titled: “Vascular Solutions and Howard Root Found Not Guilty on All Charges in Short …” and published on February 26, 2016 is yet another important article.
VASC Company Profile
Vascular Solutions, Inc., incorporated on December 20, 1996, is a medical device firm focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. The Company’s products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Firm creates minimally invasive medical devices and then delivers these products and related services to physicians through its direct domestic sales force and its international distribution network.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.